These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 12009004

  • 21. Overexpression of parathyroid hormone-related protein causes hypercalcemia but not bone metastases in a murine model of mammary tumorigenesis.
    Wysolmerski JJ, Dann PR, Zelazny E, Dunbar ME, Insogna KL, Guise TA, Perkins AS.
    J Bone Miner Res; 2002 Jul; 17(7):1164-70. PubMed ID: 12096830
    [Abstract] [Full Text] [Related]

  • 22. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
    Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM.
    J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
    [Abstract] [Full Text] [Related]

  • 23. Effects of the (1-34) fragment of synthetic parathyroid hormone-related protein on tartrate-resistant acid phosphatase and alkaline phosphatase and alkaline phosphatase activities, and on osteocalcin synthesis, in cultured fetal rat calvaria.
    Torres R, de la Piedra C, Rapado A.
    Miner Electrolyte Metab; 1993 Aug; 19(2):64-70. PubMed ID: 8377726
    [Abstract] [Full Text] [Related]

  • 24. [PTH-related protein (PTHrP) in serum of patients with tumor hypercalcemia].
    Scharla SH, Pecherstorfer M, Lempert UG, Minne HW, Sarrach M, Baumgartner G, Ziegler R.
    Med Klin (Munich); 1991 Apr 15; 86(4):186-9. PubMed ID: 2056982
    [Abstract] [Full Text] [Related]

  • 25. Malignant islet cell tumor associated with hypercalcemia.
    Mao C, Carter P, Schaefer P, Zhu L, Dominguez JM, Hanson DJ, Appert HE, Kim K, Howard JM.
    Surgery; 1995 Jan 15; 117(1):37-40. PubMed ID: 7809834
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.
    Horwitz MJ, Tedesco MB, Sereika SM, Prebehala L, Gundberg CM, Hollis BW, Bisello A, Garcia-Ocaña A, Carneiro RM, Stewart AF.
    J Bone Miner Res; 2011 Sep 15; 26(9):2287-97. PubMed ID: 21544866
    [Abstract] [Full Text] [Related]

  • 28. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
    Nakayama Y, Okuno S, Miki T, Nishizawa Y, Morii H.
    Nihon Naibunpi Gakkai Zasshi; 1992 Dec 20; 68(12):1294-9. PubMed ID: 1291340
    [Abstract] [Full Text] [Related]

  • 29. [Malignant humoral hypercalcemia and the parathyroid hormone related protein].
    Jemtland R, Rian E, Gautvik KM.
    Tidsskr Nor Laegeforen; 1991 May 30; 111(14):1738-42. PubMed ID: 2063384
    [Abstract] [Full Text] [Related]

  • 30. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study.
    Szulc P, Munoz F, Marchand F, Chapuy MC, Delmas PD.
    Calcif Tissue Int; 2003 Dec 30; 73(6):520-30. PubMed ID: 12958693
    [Abstract] [Full Text] [Related]

  • 31. Effects of infusion of human parathyroid hormone-related protein-(1-40) in nude mice: histomorphometric and biochemical investigations.
    Rosol TJ, Capen CC, Horst RL.
    J Bone Miner Res; 1988 Dec 30; 3(6):699-706. PubMed ID: 2855193
    [Abstract] [Full Text] [Related]

  • 32. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
    Takeuchi Y.
    Clin Calcium; 2011 Jan 30; 21(1):28-32. PubMed ID: 21187591
    [Abstract] [Full Text] [Related]

  • 33. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.
    Plotkin H, Gundberg C, Mitnick M, Stewart AF.
    J Clin Endocrinol Metab; 1998 Aug 30; 83(8):2786-91. PubMed ID: 9709948
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1.
    Milanesi A, Yu R, Geller SA, Burton D, Deftos LJ, Wolin EM.
    Pancreas; 2011 May 30; 40(4):634-7. PubMed ID: 21483254
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia].
    Okazaki R.
    Clin Calcium; 2010 Oct 30; 20(10):1497-502. PubMed ID: 20890031
    [Abstract] [Full Text] [Related]

  • 38. Parathyroid hormone (PTH)-related protein, PTH, and 1,25-dihydroxyvitamin D in dogs with cancer-associated hypercalcemia.
    Rosol TJ, Nagode LA, Couto CG, Hammer AS, Chew DJ, Peterson JL, Ayl RD, Steinmeyer CL, Capen CC.
    Endocrinology; 1992 Sep 30; 131(3):1157-64. PubMed ID: 1505457
    [Abstract] [Full Text] [Related]

  • 39. Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism.
    Parfitt AM, Schipani E, Rao DS, Kupin W, Han ZH, Jüppner H.
    J Clin Endocrinol Metab; 1996 Oct 30; 81(10):3584-8. PubMed ID: 8855805
    [Abstract] [Full Text] [Related]

  • 40. Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy.
    Syed MA, Horwitz MJ, Tedesco MB, Garcia-Ocaña A, Wisniewski SR, Stewart AF.
    J Clin Endocrinol Metab; 2001 Apr 30; 86(4):1525-31. PubMed ID: 11297578
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.